Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERA Vera Therapeutics, Inc.

Post-Mkt 07-16 16:24:04 EDT

39.12

-3.38

-7.95%

盘后39.71

+0.59+1.51%

16:17 EDT

High42.60	Low39.09	Vol1.61M
Open42.26	D1 Closing42.50	Amplitude8.25%
Mkt Cap2.81B	Tradable Cap2.04B	Total Shares71.71M
T/O64.26M	T/O Rate3.09%	Tradable Shares52.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VERA","market":"US","secType":"STK","nameCN":"Vera Therapeutics, Inc.","latestPrice":39.12,"timestamp":1784232000000,"preClose":42.5,"halted":0,"volume":1610662,"hourTrading":{"tag":"盘后","latestPrice":39.71,"preClose":39.12,"latestTime":"16:17 EDT","volume":27563,"amount":1079120.11552,"timestamp":1784233054865,"change":0.59,"changeRate":0.015082,"amplitude":0.021472},"delay":0,"changeRate":-0.07952941176470595,"floatShares":52073900,"shares":71713905,"eps":-5.574565,"marketStatus":"Post-Mkt","change":-3.38,"latestTime":"07-16 16:24:04 EDT","open":42.26,"high":42.595,"low":39.09,"amount":64258043.410688,"amplitude":0.082471,"askPrice":40.4,"askSize":200,"bidPrice":39,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-5.574565,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1784246400000},"marketStatusCode":4,"adr":0,"listingDate":1620964800000,"exchange":"NASDAQ","adjPreClose":42.5,"preHourTrading":{"tag":"盘前","latestPrice":42.19,"preClose":42.5,"latestTime":"09:28 EDT","volume":1409,"amount":60029.509424,"timestamp":1784208480017,"change":-0.31,"changeRate":-0.007294,"amplitude":0.021412},"postHourTrading":{"tag":"盘后","latestPrice":39.71,"preClose":39.12,"latestTime":"16:17 EDT","volume":27563,"amount":1079120.11552,"timestamp":1784233054865,"change":0.59,"changeRate":0.015082,"amplitude":0.021472},"volumeRatio":0.630256,"impliedVol":0.6743,"impliedVolPercentile":0.2669},"requestUrl":"/m/hq/s/VERA","defaultTab":"news","newsList":[{"id":"2651100961","title":"Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Vera Therapeutics (VERA) and Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651100961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651100961?lang=en_us&edition=fundamental","pubTime":"2026-07-13 23:00","pubTimestamp":1783954842,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Immuneering (IMRX), Vera Therapeutics (VERA) and A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-vera-therapeutics-vera-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-vera-therapeutics-vera-and-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","HCSG","LU0109394709.USD","BK4581","BK4137","LU2324357040.USD","LABU","BK4588","LU0882574055.USD","XLV","LU0889565916.HKD","IMRX","PBE","LU0320765992.SGD","XBI","BK4585","BK4563","LU0114720955.EUR","BK4548","LU0029874061.USD","BK4539","BK4139","ALNY","VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650296159","title":"Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650296159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650296159?lang=en_us&edition=fundamental","pubTime":"2026-07-11 22:30","pubTimestamp":1783780221,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vera-therapeutics-vera-crinetics-pharmaceuticals-crnx-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vera-therapeutics-vera-crinetics-pharmaceuticals-crnx-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA","BK4539","PTH","IE00B2B36J28.USD","RVMD","IE00BJJMRZ35.SGD","BK4139","BK4007","IE0002141913.USD","XBI","LU0320765992.SGD","LABU","LU0029874061.USD","BK4585","BK4588","IE00BFTCPJ56.SGD","LU0109394709.USD","BK4581","IDNA","IE0009355771.USD","LU0889565916.HKD","LU2324357040.USD","LU0128526141.USD","CRNX","IE00B4R5TH58.HKD","BBH","XLV","HCSG","CANC","BK4137","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650132795","title":"Vera Therapeutics Grants Inducement Equity Awards to Eight New Hires, Sets Options at $40.13 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2650132795","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650132795?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:05","pubTimestamp":1783713942,"startTime":"0","endTime":"0","summary":"Vera Therapeutics grants inducement equity awards to eight new hires, sets options at $40.13 per shareVera Therapeutics granted inducement equity awards to eight new hires under its 2024 Inducement Pl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL2LNYG7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014039.USD","LU2324357040.USD","BCDF","LU0314104364.USD","BK4588","SG9999014021.USD","NDAQ","BK4585","VERA","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","BK4139","IE00BGHQF748.EUR","LU2210150020.SGD","LU2210149790.SGD","BK4112","BK4539","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650137321","title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650137321","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650137321?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:05","pubTimestamp":1783713900,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., July  10, 2026  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/10/3325748/0/en/Vera-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","BK4585","BK4588","LU2324357040.USD","VERA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650972840","title":"Vera Therapeutics CEO Fordyce Marshall Sells 46,250 Shares for $1.96 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2650972840","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650972840?lang=en_us&edition=fundamental","pubTime":"2026-07-10 04:45","pubTimestamp":1783629940,"startTime":"0","endTime":"0","summary":"Vera Therapeutics CEO Fordyce Marshall sells 46,250 shares for $1.96 millionVera Therapeutics President and CEO Marshall Fordyce sold 46,250 Class A common shares on July 7, 2026.Sales were priced at ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDLpHVTx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vera Therapeutics CEO Fordyce Marshall Sells 46,250 Shares for $1.96 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4539","LU2324357040.USD","VERA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650069929","title":"Vera Therapeutics Names Nancy Bowman Chief Regulatory Officer, Replacing William Turner","url":"https://stock-news.laohu8.com/highlight/detail?id=2650069929","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650069929?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:01","pubTimestamp":1783598488,"startTime":"0","endTime":"0","summary":"Vera Therapeutics names Nancy Bowman chief regulatory officer, replacing William TurnerVera Therapeutics named Nancy Bowman, M.D., Ph.D., as chief regulatory officer, effective Aug. 3, 2026.William Tu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDL8BJwpp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2324357040.USD","VERA","BK4139","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650929086","title":"Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner","url":"https://stock-news.laohu8.com/highlight/detail?id=2650929086","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650929086?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:00","pubTimestamp":1783598405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nTUA4CNYGQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","LU2324357040.USD","VERA","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650131749","title":"Vera Therapeutics' Trutakna Pricing Tops Expectations, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2650131749","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650131749?lang=en_us&edition=fundamental","pubTime":"2026-07-09 03:03","pubTimestamp":1783537390,"startTime":"0","endTime":"0","summary":"Vera Therapeutics  priced its newly approved Trutakna at about $425,000 annually, above Wedbush's expectations, as the drug is expected to become available within three to four weeks, the brokerage said in a note Wednesday.Wedbush also said the pricing \"appears to be a premium\" to Otsuka's Voyxact.\"Where we have more concern is on the commercialization activities and how Trutakna will be positioned versus other monthly APRIL-targeted therapies,\" the brokerage said.Wedbush maintained its neutral rating and raised its price target to $43 from $35.Price: 41.44, Change: -1.52, Percent Change: -3.54","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VERA","BK4588","BK4139","LU2324357040.USD","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649799979","title":"Vera Therapeutics (VERA) Receives a Buy from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2649799979","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649799979?lang=en_us&edition=fundamental","pubTime":"2026-07-08 21:35","pubTimestamp":1783517734,"startTime":"0","endTime":"0","summary":"Jefferies analyst maintained a Buy rating on Vera Therapeutics today and set a price target of $60.00. In addition to Jefferies, Vera Therapeutics ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vera-therapeutics-vera-receives-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vera-therapeutics-vera-receives-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4585","BK4588","VERA","LU2324357040.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649962569","title":"Remitly Stock And 2 More Growth Picks With Strong Earnings Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2649962569","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649962569?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:34","pubTimestamp":1783514051,"startTime":"0","endTime":"0","summary":"With inflation pressures flaring again, bond yields climbing in major markets and energy shocks rippling through everything from housing to food, many investors are looking for stocks with solid finances and clear earnings growth potential. That is exactly what the Healthy high growth potential screener aims to filter for, focusing on companies that analysts expect to grow earnings strongly over the next 3 years while still meeting basic balance sheet checks. In this article, you will see 3...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/7121000-choice1-main-header/1585186619635","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7121000-choice1-main-header/1585186619635"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/diversified-financials/nasdaq-rely/remitly-global/news/remitly-stock-and-2-more-growth-picks-with-strong-earnings-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/diversified-financials/nasdaq-rely/remitly-global/news/remitly-stock-and-2-more-growth-picks-with-strong-earnings-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4227","RELY","BK4157","BK4106","BK4588","DECU","BK6522","QTOC","LU0757428866.USD","GXDW","IE00B66KJ199.SGD","VOTE","IE0031619046.USD","AEIS","AIPO","LU2324357040.USD","AGIX","IE00B19Z4B17.USD","CHAT","BK4539","FEBU","IE00B7SZL793.SGD","LU1815336091.USD","BK4139","VERA","LU0053671581.USD","VGFPF","VTHR","BK4585","BLZ.SI","BK6088","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649960160","title":"Wedbush Raises Price Target on Vera Therapeutics to $43 From $35, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2649960160","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649960160?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:49","pubTimestamp":1783507753,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) has an average rating of buy and mean price target of $80.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649696723","title":"Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX) and Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649696723","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649696723?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:20","pubTimestamp":1783506022,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Meiragtx Holdings (MGTX) and Vera Therapeutics (VERA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-meiragtx-holdings-mgtx-and-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-meiragtx-holdings-mgtx-and-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","LU2324357040.USD","XBI","BK4539","LABU","MGTX","LU0029874061.USD","BK4137","LU0128526141.USD","BK4581","VERA","XLV","HCSG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649752957","title":"Vera Therapeutics, Inc : Guggenheim Raises Target Price to $76 from $56","url":"https://stock-news.laohu8.com/highlight/detail?id=2649752957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649752957?lang=en_us&edition=fundamental","pubTime":"2026-07-08 12:59","pubTimestamp":1783486746,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nFWN439118:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VERA","BK4588","BK4539","LU2324357040.USD","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649955926","title":"Maintaining a Buy on Vera: Commercial-Stage Transition and Trutakna Strength Support Unchanged $90 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2649955926","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649955926?lang=en_us&edition=fundamental","pubTime":"2026-07-08 07:55","pubTimestamp":1783468522,"startTime":"0","endTime":"0","summary":"Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Vera Therapeutics. The associated price target remains the same with $...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maintaining-a-buy-on-vera-commercial-stage-transition-and-trutakna-strength-support-unchanged-90-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maintaining-a-buy-on-vera-commercial-stage-transition-and-trutakna-strength-support-unchanged-90-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4539","VERA","LU2324357040.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649930977","title":"Vera Therapeutics Exec Says Trutakna's Wholesale Acquisition Cost for Four Doses or 28-day Supply is $32,700 - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2649930977","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649930977?lang=en_us&edition=fundamental","pubTime":"2026-07-08 04:43","pubTimestamp":1783457025,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN43913A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4539","VERA","LU2324357040.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649329179","title":"Vera Therapeutics is Maintained at Buy by B of a Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2649329179","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649329179?lang=en_us&edition=fundamental","pubTime":"2026-07-08 03:04","pubTimestamp":1783451040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings(END) Dow Jones NewswiresJuly 07, 2026 15:04 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649932812","title":"Under the Radar: Vera Stock Jumps as Kidney-disease Drug Approved by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2649932812","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649932812?lang=en_us&edition=fundamental","pubTime":"2026-07-08 02:43","pubTimestamp":1783449780,"startTime":"0","endTime":"0","summary":"Shares of Vera Therapeutics rose about 8% Tuesday after the Food and Drug Administration approved its treatment for a kidney disease, IgA nephropathy, that affects about 160,000 people in the U.S. and often leads to kidney failure.The drug, called Trutakna, works by blocking two proteins that push the immune system to make antibodies that build up in the kidneys and cause damage. It is the first drug approved in the U.S. that targets both proteins at once, though several other drugs already treat the disease. Vertex Pharmaceuticals is chasing a similar drug that also blocks both proteins, which the FDA is due to rule on later this year.-- The accelerated approval was based on an interim look at Vera's ongoing Phase 3 trial, before the study is complete. Patients on Trutakna saw a 46% drop in a urine-protein marker doctors use to track kidney damage. That equated to a 42% bigger drop than placebo patients saw.-- \"We've really changed expectations for the disease,\" said Dr. Richard Lafay","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","IDNA","LU0432979614.USD","LU0289739699.SGD","LU2456880835.USD","SGXZ57979304.SGD","BK4539","LU0061475181.USD","IBBQ","LU1430594728.SGD","VRTX","BK4567","BBH","IE00BZ9MQY76.HKD","LU1035775433.USD","IE00B19Z9Z06.USD","BK4532","LU2236285917.USD","LU0079474960.USD","LU2462157665.USD","IE0002141913.USD","LU1093756325.SGD","IE00BJJMRZ35.SGD","IE0002270589.USD","LU2417539215.USD","LU1674673428.USD","LU0058720904.USD","IE00B2B36J28.USD","VERA","LU1674673691.USD","IE00BFTCPJ56.SGD","LABU","LU2362540622.SGD","LU0889565916.HKD","IBB","LU1069344957.HKD","LU0823416689.USD","IE00B19Z3B42.SGD","LU1093756168.USD","IE00B4R5TH58.HKD","LU2324357040.USD","PBE","IE00B19Z3581.USD","BIB","LU1585245621.USD","LU2237438978.USD","BK4588","LU0320765992.SGD","LU2362541513.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649342939","title":"Vera Therapeutics price target raised to $70 from $65 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2649342939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649342939?lang=en_us&edition=fundamental","pubTime":"2026-07-08 02:10","pubTimestamp":1783447810,"startTime":"0","endTime":"0","summary":"BofA raised the firm’s price target on Vera Therapeutics (VERA) to $70 from $65 and keeps a Buy rating on the shares following Trutakna’s condition...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-raised-to-70-from-65-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-raised-to-70-from-65-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649931720","title":"Vera Therapeutics gains FDA nod for TRUTAKNA launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2649931720","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649931720?lang=en_us&edition=fundamental","pubTime":"2026-07-08 01:18","pubTimestamp":1783444688,"startTime":"0","endTime":"0","summary":"An announcement from Vera Therapeutics ( ($VERA) ) is now available. On July 7, 2026, Vera Therapeutics announced that the U.S. Food and Drug Admin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vera-therapeutics-gains-fda-nod-for-trutakna-launch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vera-therapeutics-gains-fda-nod-for-trutakna-launch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4539","BK4585","LU2324357040.USD","BK4139","VERA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649931640","title":"Vera Therapeutics' Drug to Reduce Proteinuria Gets FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2649931640","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649931640?lang=en_us&edition=fundamental","pubTime":"2026-07-08 00:52","pubTimestamp":1783443137,"startTime":"0","endTime":"0","summary":"Vera Therapeutics'  Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement.Trutakna is injected subcutaneously once weekly, the FDA said.IgA nephropathy is a serious kidney disease that occurs when an abnormal form of an immunoglobulin A antibody builds up in the kidneys, causing kidney inflammation and damage, it said.The drug also received priority review and breakthrough therapy designation for the indication, according to the FDA.Shares were up over 6% in afternoon trading.Price: 42.89, Change: +2.76, Percent Change: +6.88","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VERA","LABU","BK4588","BK4539","LU2324357040.USD","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veratx.com","stockEarnings":[{"period":"1week","weight":0.0016},{"period":"1month","weight":0.2412},{"period":"3month","weight":0.0062},{"period":"6month","weight":-0.0862},{"period":"1year","weight":0.8319},{"period":"ytd","weight":-0.1607}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0},{"period":"3month","weight":0.0757},{"period":"6month","weight":0.0913},{"period":"1year","weight":0.2132},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.057587},{"month":2,"riseRate":0.4,"avgChangeRate":0.015839},{"month":3,"riseRate":0.4,"avgChangeRate":-0.047765},{"month":4,"riseRate":0,"avgChangeRate":-0.103447},{"month":5,"riseRate":0.2,"avgChangeRate":-0.049498},{"month":6,"riseRate":0.5,"avgChangeRate":0.171762},{"month":7,"riseRate":0.666667,"avgChangeRate":0.113099},{"month":8,"riseRate":0.6,"avgChangeRate":0.019112},{"month":9,"riseRate":0.6,"avgChangeRate":0.088867},{"month":10,"riseRate":0.2,"avgChangeRate":-0.071412},{"month":11,"riseRate":0.8,"avgChangeRate":0.292871},{"month":12,"riseRate":0.6,"avgChangeRate":0.07812}],"exchange":"NASDAQ","name":"Vera Therapeutics, Inc.","nameEN":"Vera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vera Therapeutics, Inc.,VERA,Vera Therapeutics, Inc.股票,Vera Therapeutics, Inc.股票老虎,Vera Therapeutics, Inc.股票老虎国际,Vera Therapeutics, Inc.行情,Vera Therapeutics, Inc.股票行情,Vera Therapeutics, Inc.股价,Vera Therapeutics, Inc.股市,Vera Therapeutics, Inc.股票价格,Vera Therapeutics, Inc.股票交易,Vera Therapeutics, Inc.股票购买,Vera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}